Acellbia® as a substitution for MabThera® in the monotherapy for the CD-positive B-cell non-Hodgkin's lymphoma

Download in PDF

Aim

Material and methods

We searched for the prospective randomized clinical trials that evaluated the efficacy and safety of different brands of rituximab for the treatment of the Bcell non-Hodgkin's lymphoma. Cost-minimization analysis of Acellbia® and MabThera® treatment was conducted from the perspective of the Russian healthcare system.

Results

One randomised controlled trial showed similar efficacy and safety of Acellbia® and MabThera® in the treatment for the CD-positive follicular non-Hodgkin's lymphoma. Substitution with Acellbia® for MabThera® was associated with cost-saving of RUB 34,913-46,824 for a single administration and RUB 139,654-187,294 for the course of therapy.

Conclusion

Substitution of MabThera® with Acellbia® in the monotherapy for the CD-positive B-cell follicular nonHodgkin's lymphoma is justified clinically and economically.

Key words

Rituximab, non-Hodgkin's lymphoma, import substitution.